Journal of Clinical Immunology & Immunotherapy Category: Clinical Type: Short Commentary

Action of the Proteasome Activator REGγ in Autoimmune Diseases

Liangfang Yao1, Yang Xuan1, Xiaotao Li2* and Bianhong Zhang1*
1 Shanghai key laboratory of regulatory biology, Institute of Biomedical Sciences, School of Life Sciences, East China Normal University, 500 Dongchuan Road, Shanghai, 200241, China
2 Department of molecular and cellular biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, United states

*Corresponding Author(s):
Xiaotao Li
Department Of Molecular And Cellular Biology, Baylor College Of Medicine, One Baylor Plaza, Houston, TX 77030, United States
Bianhong Zhang
Shanghai Key Laboratory Of Regulatory Biology, Institute Of Biomedical Sciences, School Of Life Sciences, East China Normal University, 500 Dongchuan Road, Shanghai, 200241, China
#Equal contribution

Received Date: Aug 15, 2020
Accepted Date: Aug 21, 2020
Published Date: Aug 28, 2020


Systemic lupus erythematosus (SLE) is a common autoimmune disease with multiple systems and organs damaged [1]. Lupus nephritis (LN) is one of the most serious complications in SLE and almost all SLE patients have varying degrees of renal lesions which directly affect the prognosis of SLE [2]. About 60% of SLE patients have LN, and 10%~30% of patients eventually develop renal failure [3]. The pathogenesis of SLE is complex and has yet to be clearly explained, resulting in a lack of effective targeted therapy in clinical practice.

Several studies have shown that CD8+ T cells, Dendritic cells (DCs) and immunoproteasomes play crucial roles in autoimmune diseases. In SLE patients, the number of CD8+ T cells are expanded [4,5] and the expression of costimulatory molecules CD40/CD86 on DC are increased [6,7]. Mice depleted the proteolytic β subunits of immunoproteasome LMP2, LMP7, or MECL1 have a significantly decrease in the generation of MHC class I ligands [8]. In contrast, depletion of CD8+ T cells ameliorates symptoms in experimental autoimmune glomerulonephritis, experimental autoimmune myasthenia gravis and several rheumatoid arthritis (RA) models [5,9]. Inhibition of the immunoproteasome also ameliorates symptoms in SLE and RA models [10,11].

The activity of the proteasome is drastically enhanced by three classes of proteasome activator complexes: 19S (or PA700), 11S (or PA28) and PA200 [12]. 11S proteasome activator, which contains three family members with molecular weight of 28kDa: REGα, REGβ and REGγ, is involved in ubiquitin- and ATP-independent protein degradation pathway [13,14]. While REGα and REGβ has been shown that control immunoproteasome to process antigens for MHC class I ligands presentation [15-18], the biological functions of REGγ in immune system has not been fully characterized. Until recently, Dr. Li's research group at East China Normal University has reported for the first time that REGγ plays a regulatory role in autoimmune diseases by inhibiting immunoproteasome [19]. This work, entitled "The proteasome activator REGγ counteracts immunoproteasome expression and autoimmunity", has been published in Journal of Autoimmunity.

In this article, the authors demonstrate that REGγ functions as an inhibitor of immunoproteasome using samples from REGγ-deficient mice and lupus nephritis patients. Mice lack of REGγ have elevated CD8+ T cells, DCs, and develop age-related spontaneous autoimmune symptoms, which are exacerbated in the Pristane-induced lupus model. Mechanistically, REGγ interacts with phosphorylated STAT3 and leads degradation in an ubiquitin-independent manner, inhibiting the transcription of its downstream target genes LMP2/LMP7 and eventually attenuating MHC class I-restricted antigen presentation by DCs. Inhibition of STAT3 significantly diminishs LMP2/LMP7 expression and antigen presentation in REGγ-/- DCs, while treatment with STAT3 or LMP2/7 inhibitors results in less accumulation of immune complexes in kidneys from REGγ KO mice. In addition, the authors have revealed an inverse correlation between REGγ (low) and phosphorylated STAT3, LMP2, and LMP7 (high) in human Lupus Nephritis in clinical samples.

Recently, the same group has published a second report that REGγ-mediated regulation of DCs controls the differentiation of Th17 cell and the pathogenesis of experimental autoimmune disease [20], indicating again that REGγ deficiency is associated with autoimmune diseases. The function and mechanism of REGγ in other autoimmune diseases deserve further investigation.

Taken together, it has been shown for the first time that the proteasome activator REGγ is a new regulator for antigen presentation and autoimmunity. PR-957, a promising LMP7 specific inhibitor, has been validated in several autoimmune disease mice models [21,22], demonstrating importance of immunoproteasome in autoimmunity. The current results suggest that targeting REGγ-proteasome abnormalities, rather than direct intervention in systemic immunity, may be an important and feasible strategy for the treatment of LN, providing a new idea for targeted therapeutic options for LN.


  1. Cozzani E, Drosera M, Gasparini G, Parodi A (2014) Serology of Lupus Erythematosus: Correlation between Immunopathological Features and Clinical Aspects. Autoimmune Diseases 2014: 321359.
  2. De Zubiria Salgado A, Herrera Diaz C (2012) Lupus nephritis: An overview of recent findings. Autoimmune Diseases 2012: 849684.
  3. Inda Filho A, Neugarten J, Putterman C, Broder A (2013) Improving outcomes in patients with lupus and end-stage renal disease. Semin Dial 26: 590-596.
  4. Linker Israeli M, Quismorio FP, Horwitz DA (1990) CD8+ Lymphocytes from patients with systemic lupus erythematosus sustain, rather than suppress, spontaneous polyclonal IgG production and synergize with CD4+ cells to support autoantibody synthesis. Arthritis Rheum 33: 1216-1225.
  5. Gravano DM, Hoyer KK (2013) Promotion and prevention of autoimmune disease by CD8+ T cells. J Autoimmun 45: 68-79.
  6. Mackern Oberti JP, Llanos C, Vega F, Onfray FZ, Riedel CA, et al. (2015) Role of dendritic cells in the initiation, progress and modulation of systemic autoimmune diseases. Autoimmun Rev 14: 127-139.
  7. Carreño LJ, Pacheco R, Gutierrez MA, Jacobelli S, Kalergis AM (2009) Disease activity in systemic lupus erythematosus is associated with an altered expression of low-affinity Fc gamma receptors and costimulatory molecules on dendritic cells. Immunology 128: 334-341.
  8. Kincaid EZ, Che JW, York I, Escobar H, Vargas ER, et al. (2011) Mice completely lacking immunoproteasomes show major changes in antigen presentation. Nat Immunol 13: 129-135.
  9. Kang YM, Zhang X, Wagner UG, Yang H, Beckenbaugh RD, et al. (2002) CD8 T cells are required for the formation of ectopic germinal centers in rheumatoid synovitis. J Exp Med 195: 1325-1336.
  10. Muchamuel T, Basler M, Aujay MA, Suzuki E, Kalim KW, et al. (2009) A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med 15: 781-787.
  11. Ichikawa HT, Conley T, Muchamuel T, Jiang J, Lee S, et al. (2012) Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells. Arthritis Rheum 64: 493-503.
  12. Vigneron N, Van den Eynde BJ (2014) Proteasome subtypes and regulators in the processing of antigenic peptides presented by class I molecules of the major histocompatibility complex. Biomolecules 4: 994-1025.
  13. Ma CP, Slaughter CA, DeMartino GN (1992) Identification, purification, and characterization of a protein activator (PA28) of the 20 S proteasome (macropain). J Biol Chem 267: 10515-10523.
  14. Dubiel W, Pratt G, Ferrell K, Rechsteiner M (1992) Purification of an 11 S regulator of the multicatalytic protease. J Biol Chem 267: 22369-22377.
  15. Rechsteiner M, Realini C, Ustrell V (2000) The proteasome activator 11 S REG (PA28) and class I antigen presentation. Biochem J 345: 1-15.
  16. Murata S, Udono H, Tanahashi N, Hamada N, Watanabe K, et al. (2001) Immunoproteasome assembly and antigen presentation in mice lacking both PA28alpha and PA28beta. EMBO J 20: 5898-5907.
  17. Kloetzel PM, Ossendorp F (2004) Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. CurrOpin Immunol 16: 76-81.
  18. Rivett AJ, Hearn AR (2004) Proteasome function in antigen presentation: immunoproteasome complexes, Peptide production, and interactions with viral proteins. Curr Protein Pept Sci 5: 153-161.
  19. Yao L, Zhou L, Xuan Y, Zhang P, Wang X, et al. (2019) The proteasome activator REGγ counteracts immunoproteasome expression and autoimmunity. J Autoimmun 103: 102282.
  20. Zhou L, Yao L, Zhang Q, Xie W, Wang X, et al. (2019) REGγ controls Th17 cell differentiation and autoimmune inflammation by regulating dendritic cells. Cell Mol Immunol.
  21. Muchamuel T, Basler M, Aujay MA, Suzuki E, Kalim KW, et al. (2009) A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med 15: 781-787.
  22. Basler M, Dajee M, Moll C, Groettrup M, Kirk CJ (2010) Prevention of experimental colitis by a selective inhibitor of the immunoproteasome. J Immunol 185: 634-641.

Citation: Yao L, Xuan Y, Li X, Zhang B (2020) Action of the Proteasome Activator REGγ in Autoimmune Diseases. J Clin Immunol Immunother 6: 038.

Copyright: © 2020  Liangfang Yao, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Herald Scholarly Open Access is a leading, internationally publishing house in the fields of Sciences. Our mission is to provide an access to knowledge globally.

© 2023, Copyrights Herald Scholarly Open Access. All Rights Reserved!